MLL translocated (t-MLL) acute leukemias (AL) have long been recognised to coexpress both myeloid and lymphoid phenotypic markers, suggestive of a 'biphenotypic' or mixed lineage stage of maturation arrest.
Clonal TCRd, TCRg and IgH DJ rearrangements were searched for in 55 AMLs with MLL translocation (t-MLL), and compared to 17 AML cases with MLL-ITD and two with MLL topoisomerase II breakage (analysed collectively and referred to as MLL-ITD/ TopoII here) and with 43 MLL germline AMLs (Table 1) . IgH/ TCR rearrangements were not seen in the 25 infants/children analysed, being restricted to AML cases aged over 15 years. Among adult AML, 32% of t-MLL AMLs demonstrated TCR and/ or IgH DJ rearrangements, compared to 11% of MLL-ITD/TopoII AML and only 2% of AML with germline MLL status (P ¼ 0.001 compared to t-MLL). These differences remained statistically significant after inclusion of pediatric cases (P ¼ 0.01). IgH/TCR rearrangements were more frequent in AML FAB M1/2 (5/8) compared to M4/5 (6/31; P ¼ 0.02)
The type of IgH/TCR rearrangement differed with the MLL partner; MLL-AF6 AMLs demonstrated more frequent TCR rearrangements than other t-MLL cases (4/10 vs 3/45; P ¼ 0.01: Five AML demonstrated a total of eight rearranged TCRd alleles. Strikingly, all were T lymphoid restricted, as defined by involvement of a Jd segment. Such rearrangement require exposure to T restricted transcription factors. TCR profiles were more mature in MLL-AF6, with complete TCRd V(D)J in all three TCRd rearranged cases (Vd1-Jd1/Dd2-Jd1, Vd2-Jd1/Dd2-Jd1 and Vd2-Jd1) and a Vg9-Jg1/2 in a fourth, compared to a partial DJ in the MLL-AF9 (both Dd2-Jd1) and MLL-ENL (Dd2-Jd2) cases. MLL fusion to AF6, AF9 and ENL is well recognised in T-ALL, but none of the five TCR rearranged AML tested expressed the CD2 or CD5 T cell markers and only one expressed CD7. The Vd2-Dd3/Dd2-Dd3 'illegitimate' rearrangements frequent in BCP-ALL were not seen. All AMLs were RAG-1 negative with no difference in the levels seen in IgH/TCR þ cases (data not shown). These profiles are in keeping with early T lymphoid orientation, rather than 'illegitemate' V(D)J rearrangement resulting from exposure to recombinase activity. They suggest that TCR rearranged t(MLL) AML may be closely related to t(MLL) T-ALL.
The data presented here are in favour of a significant role for MLL partner genes in determining the stage of maturation arrest in AL at the early stages of myeloid/lymphoid specification, with consequences for both our understanding of hematopoiesis and appropriate classification of acute leukemias. They are in keeping with the existence of an initial separation of the B and T lymphoid lineages, prior to loss of myeloid/macrophage potential, as postulated 4 and also with the identification of distinct early T/NK/myeloid precursor in CD34 þ /CD7 þ / CD45 high cord blood progenitors which demonstrate T/NK potential and retain myeloid transcripts but have lost B lymphoid potential 8 and with a CD34 þ /CD19 þ /CXCR4-common B/myeloid precursor. 9 Since the incidence and type of MLL rearrangement varied with both age and fusion transcript partner, we attempted to analyse which predominated. The limited number of patients demonstrating each type of fusion transcript prevents detailed analysis, particularly since MLL-AF6 and MLL-ENL were restricted to adults. It is, however, noteworthy that 3/5 adult AML with MLL-ELL demonstrated IgH DJ rearrangement, whereas none of the three children (all infants) did so. Similarly, IgH/TCR rearrangements in AML with MLL-AF9 were restricted to adults, suggesting that both MLL partner genes and age of AML onset appear to have an influence on IgH/TCR status and/ or on presentation as ALL or AML. This is similar to the influence of age on T-ALL. 5 It is noteworthy that MLL-ENL is associated with AML in adults, as in this series, but is commonly found in ALL in infants and children, when MLL-AF4, AF9 and ENL predominate. Centralised detailed genetic evaluation of t-MLL AL will contribute to improved evaluation of the influence of age and fusion transcript partner on MLL induced maturation arrest at the early stages of myeloid/lymphoid specification. It will also aid appropriate therapeutic stratification of this group of poor prognosis AL. 
